<DOC>
	<DOCNO>NCT00387192</DOCNO>
	<brief_summary>The main objective study ass pharmacokinetics OPTIVATE® single dose 80 IU/kg VWF : RCo . The secondary objective study assess efficacy safety OPTIVATE® long-term use least 12 month .</brief_summary>
	<brief_title>A Study With OPTIVATE® People With Von Willebrand Disease</brief_title>
	<detailed_description />
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Have give write informed consent . 2 . Be age 12 year old . 3 . Have severe VWD ( VWF : RCo &lt; 20 % ) know type . Severity confirm current VWF : RCo result &lt; 20 % . 4 . Be know expected require concentrate management VWD . 5 . Must least one bleed last 12 month require treatment FVIII VWF concentrate . 6 . Have know lack , poor response , DDAVP . 7 . Have prothrombin time ( PT ) 3 second upper limit reference range . 8 . At Baseline Visit ( Visit 1 ) , patient must least 5 day since last infusion replacement factor concentrate DDAVP . 9 . Female patient childbearing potential must negative result human chorionic gonadotropinbased pregnancy test . If female patient become sexually active , must practice contraception use method proven reliability duration study . Female patient must lactate . 1 . Have history inhibitor development VWF FVIII positive result screening . 2 . Actively bleed ( Note : patient enter study bleed control ) . 3 . Presence major systemic illness : renal disease , liver disease , neurological psychiatric disease would compromise outcome study opinion investigator . 4 . Known suspected hypersensitivity investigational medicinal product ( IMP ) excipients . 5 . Have recent history alcohol drug abuse . 6 . Administration new chemical entity within 4 month precede enrolment . 7 . Participation clinical study investigational market drug employ 30 day precede enrolment study , exception BPL clinical study Protocol 8VWF03 . 8 . In opinion investigator , patient unlikely comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Von Willebrand Disease</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Von Willebrand Factor</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>